Breakthrough technology for bladder cancer succeeds in Phase II.
Vesimune (TMX-101), has completed a Phase IIa proof-of-concept clinical trial for the localised treatment of bladder cancer.
This is a disease of seriously unmet medical need. Vesimune will be the first new targeted therapy in decades, dedicated to bladder cancer and the first compound to modulate the innate immune system for this indication. The trial has had complete responders with elimination of tumours. Telormedix is a biopharmaceutical company focused on targeted immunity and the role of the innate immune system in treating cancer and infectious diseases. CEO, Johanna Holldack talked to Adrian Dawkes at BIO International 2014 in San Diego about it's success so far and the future prospects for the therapy and the company.